Prediabetes in End Stage Renal Disease on Dialysis

Screening of Prediabetes in End Stage Renal Disease on Dialysis

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT07337083

Enrollment

262

Registered

2026-01-13

Start date

2025-04-13

Completion date

2025-10-12

Last updated

2026-01-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic Renal Failure (CRF), Dialysis Patients, Pre Diabetic, Screening

Brief summary

Prediabetes is a highly prevalent condition, affecting about one-third of adults in the United States Patients with prediabetes have an increased risk for diabetes, with 2% to 10% progressing to diabetes each yea Although prediabetes is frequently considered an intermediary stage in the progression between normoglycemia and diabetes, many individuals may have prediabetes for several years, while some may never progress.

Interventions

None listed

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* End stage renal disease on dialysis patients aged ≥ 18 years old.

Exclusion criteria

1. Patients previously diagnosed with prediabetes. 2. Patients previously diagnosed with diabetes mellitus. 3. Acute Medical Status :Hospitalized patients. 4. Physiological States: Pregnant females.Lactating females. 5. Specific Comorbidities & Conditions: Polycystic kidney disease. 6. New York Heart Association (NYHA) class III or IV heart failure. 7. Known liver cirrhosis. or HIV/AIDS. 8. Renal cancer. 9. Active immunosuppression. or Recent chemotherapy or immunosuppressive therapy. 10. History of organ transplantation.

Design outcomes

Primary

Measure	Time frame
The prevalence of prediabetes in the End Stage Renal Disease (ESRD) on dialysis cohort.	The time frame for measurement of the primary outcome (prevalence of prediabetes) with all diagnostic measurements (Fasting Plasma Glucose mg/dl) performed once per participant at the time of their inclusion in the study.

Countries

Egypt

Outcome results